SequelSEC

BICYCLE THERAPEUTICS PLC BCYC

Pharmaceutical Preparations · CIK 0001761612 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$34.06M
Fiscal year ended 2026-09-30
Operating income
-$13.48M
Fiscal year ended 2026-09-30
Free cash flow
-$40.61M
Fiscal year ended 2026-09-30

Valuation, from the filing

Public float$266.67MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float / revenue3.7×A lower bound on the multiple, because affiliate holdings are excluded.
Float / equity0.4×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Pharmaceutical Preparations filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
Current ratio11.98x84th
Revenue YoY growth105.8%84th
SBC / revenue54.4%63th
FCF margin-347.2%38th
CapEx / revenue3.2%60th
R&D / revenue331.0%58th
Net margin-301.7%44th
Operating margin-340.4%45th

BICYCLE THERAPEUTICS PLC (BCYC) reported revenue of $34.06M and net income of -$10.48M for the fiscal year ended 2026-09-30. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from BICYCLE THERAPEUTICS PLC’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

BICYCLE THERAPEUTICS PLC income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-30
Revenue$34.06M$629.00K$887.00K$47.96M$11.73M$2.92M$9.98M$3.71M$2.68M$9.36M
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$13.48M-$54.56M-$65.48M-$24.71M-$65.55M-$86.60M-$70.20M-$67.66M-$63.85M-$46.65M
Net income-$10.48M-$50.33M-$60.82M-$20.15M-$59.10M-$78.95M-$60.75M-$51.85M-$50.80M-$39.81M
Research & development$33.42M$41.16M$48.90M$51.77M$58.43M$71.03M$59.06M$49.78M$48.26M$40.06M
Weighted-average diluted sharesshares 69.98Mshares 69.80Mshares 69.68MUnavailableshares 69.30Mshares 69.25Mshares 69.20MUnavailableshares 68.99Mshares 51.99M
Pretax income-$9.31M-$50.24M-$60.65M-$18.89M-$58.90M-$79.18M-$61.84M-$52.94M-$54.25M-$39.70M
Income tax expense$1.17M$90.00K$172.00K$1.26M$205.00K-$231.00K-$1.09M-$1.08M-$3.45M$115.00K
Diluted EPS$-0.15$-0.72$-0.87Unavailable$-0.85$-1.14$-0.88Unavailable$-0.74$-0.77
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$14.11M$14.03M$17.47M$20.89M$18.86M$18.49M$21.12M$21.59M$18.26M$15.95M
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

BICYCLE THERAPEUTICS PLC balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-30
Cash & equivalents$469.93M$510.05M$559.47M$628.11M$648.32M$721.45M$792.97M$879.52M$890.86M$961.36M
Total assets$567.18M$606.58M$652.40M$717.60M$763.95M$832.18M$883.89M$956.87M$996.75M$1.06B
Current assets$537.56M$575.24M$619.14M$682.88M$738.82M$804.26M$856.09M$928.60M$966.19M$1.03B
Total liabilities$61.90M$96.32M$98.08M$107.62M$145.48M$163.27M$143.56M$163.81M$165.71M$183.54M
Current liabilities$44.46M$47.64M$48.89M$56.98M$69.28M$77.42M$57.62M$67.23M$56.40M$69.61M
Total equity incl. NCI$505.28M$510.26M$554.32M$609.98M$618.48M$668.92M$740.33M$793.06M$831.03M$873.81M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailable$0UnavailableUnavailable$136.00K$0Unavailable$233.00K
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable$8.50M
Accounts payable$9.59M$5.66M$5.97M$9.67M$12.65M$18.26M$11.11M$15.79M$5.71M$7.45M

Cash flow

BICYCLE THERAPEUTICS PLC cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-30
Operating cash flow-$40.30M-$49.61M-$65.92M-$19.35M-$71.17M-$72.79M-$86.37M-$9.40M-$39.83M-$44.63M
Capital expenditures$305.00K$265.00K$713.00K$574.00K$674.00K$498.00K$604.00K$368.00K$435.00K$420.00K
Investing cash flow-$305.00K-$265.00K-$713.00K-$574.00K-$674.00K-$498.00K-$604.00K-$368.00K-$435.00K-$420.00K
Financing cash flow-$31.00K-$50.00K-$54.00K-$15.00K-$30.00K-$45.00K-$41.00K$203.00K-$31.93M$549.61M
Net change in cash-$40.12M-$49.97M-$68.64M-$20.16M-$73.13M-$71.52M-$86.55M-$11.34M-$70.50M$504.37M
Stock-based compensation$5.42M$6.40M$6.93M$11.65M$8.77M$9.44M$9.60M$10.33M$9.20M$9.26M
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$1.10M$1.10M$1.13M$1.30M$1.80M$1.70M$1.63M$1.70M$2.20M$1.60M

Derived

BICYCLE THERAPEUTICS PLC derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-30
Free cash flow-$40.61M-$49.87M-$66.64M-$19.92M-$71.85M-$73.28M-$86.97M-$9.76M-$40.27M-$45.05M
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating margin-39.6%-8673.9%-7382.4%-51.5%-558.6%-2965.8%-703.7%-1824.8%-2385.9%-498.3%
FCF margin-119.2%-7928.6%-7512.7%-41.5%-612.3%-2509.7%-871.7%-263.3%-1504.7%-481.2%
SBC / revenue15.9%1018.1%781.3%24.3%74.7%323.1%96.3%278.7%343.9%99.0%
Current ratio12.09x12.08x12.66x11.98x10.66x10.39x14.86x13.81x17.13x14.77x
Revenue YoY growth190.2%-78.5%-91.1%1193.3%338.5%-68.8%-48.9%-30.4%-50.0%-17.9%
Net margin-30.8%UnavailableUnavailable-42.0%-503.7%UnavailableUnavailable-1398.4%-1898.4%Unavailable
R&D / revenue98.1%6543.7%5513.1%108.0%497.9%2432.5%591.9%1342.4%1803.6%427.9%
CapEx / revenue0.9%42.1%80.4%1.2%5.7%17.1%6.1%9.9%16.3%4.5%
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open BCYC in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-10-29View SEC filing
10-Q · Filed 2026-07-30View SEC filing
10-Q · Filed 2026-04-30View SEC filing
10-K · Filed 2026-03-17View SEC filing
10-Q · Filed 2025-10-30View SEC filing
10-Q · Filed 2025-08-08View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.